| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BFGF; FGFB; FGF-2; HBGF-2 |
| Entrez GeneID | 2247 |
| clone | 1A9B2 |
| WB Predicted band size | 30.8kd |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human FGF2 (AA: 189-288) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4条关于FGF2抗体的参考文献示例(内容基于常见研究主题构造，非真实文献)：
1. **"Neutralizing FGF2 Antibody Inhibits Tumor Angiogenesis and Growth in Xenograft Models"**
- **作者**: Smith A, et al.
- **摘要**: 研究利用特异性FGF2抗体阻断肿瘤微环境中的FGF2信号，显著抑制小鼠模型中肿瘤血管生成和肿瘤生长，提示其治疗潜力。
2. **"Development of a High-Affinity FGF2 Antibody for Western Blot and Immunohistochemistry Applications"**
- **作者**: Johnson R, et al.
- **摘要**: 报道一种新型高亲和力兔源FGF2抗体的开发，验证其在多种组织样本中的特异性，适用于Western Blot和免疫组化检测。
3. **"FGF2 Neutralization Reduces Fibrosis in a Mouse Model of Chronic Kidney Disease"**
- **作者**: Lee H, et al.
- **摘要**: 通过FGF2抗体中和病理状态下的FGF2活性，显著减轻小鼠肾脏纤维化，为靶向FGF2的疾病干预提供依据。
4. **"Cross-Reactivity Analysis of Anti-FGF2 Antibodies Across Species Reveals Conserved Epitopes"**
- **作者**: García M, et al.
- **摘要**: 评估多种FGF2抗体的种属交叉反应性，发现部分抗体在人、小鼠和大鼠中均能识别保守表位，支持跨物种研究应用。
(注：以上为示例性内容，实际文献需通过学术数据库检索。)
Fibroblast Growth Factor 2 (FGF2) antibodies are essential tools for studying the multifaceted roles of FGF2. a heparin-binding protein involved in cell proliferation, angiogenesis, tissue repair, and embryonic development. FGF2. also known as basic FGF, signals through FGFR tyrosine kinase receptors, activating downstream pathways like MAPK and PI3K/AKT. Its dysregulation is linked to cancer, fibrosis, and inflammatory diseases.
FGF2 antibodies, including monoclonal and polyclonal types, are designed to detect, quantify, or neutralize FGF2 in research and clinical settings. They enable techniques such as Western blotting, immunohistochemistry, ELISA, and flow cytometry to localize FGF2 expression in tissues or measure its levels in biological fluids. Neutralizing antibodies specifically block FGF2-receptor interactions, aiding mechanistic studies in tumor growth, wound healing, and stem cell differentiation.
Therapeutic applications are emerging, with FGF2-targeting antibodies explored for anti-cancer therapies and regenerative medicine. However, challenges remain due to FGF2’s structural complexity, splice variants, and cross-reactivity with related FGF family members. Validation of antibody specificity is critical to ensure accurate experimental and diagnostic outcomes. Ongoing research focuses on optimizing antibody affinity and developing bispecific formats to enhance clinical efficacy against FGF2-driven pathologies.
×
